drugset / Trial / NCT02923258

Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer

NCT02923258

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized,controled, phase II, open label study of postoperative concurrent chemoradiotherapy with Docetaxel versus Cisplatin for high-risk squamous cell carcinoma of the oral cavity cancer.The primary purpose of this study is to evaluate the efficacy of concurrent chemoradiotherapy with docetaxel in OCC patients.

Timeline

Start
2018-04-21
Primary completion
2022-02-28
Completion
2023-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cisplatin Other / unclassified 100 mg/m2
Subject Docetaxel Small molecule 20 mg/m2